Cyto, some PR's are not meant to move the needle,
Post# of 155666
(Total Views: 467)
Posted On: 04/07/2020 8:48:22 AM
Cyto, some PR's are not meant to move the needle, some are just informational such as the FOX Business news update now today at 2 pm and of course the UK's Emergency access to Leronlimab. Also, I think we are all spoiled (including myself) on the numerous updates we receive, but these times are different with the COVID-19. As for initial PR's on China, Taiwan and others I really think the terms were bad and the USA outbreak gave precedent over everything else as well it should in this global pandemic. All the global news we have seen for Cytodyn in the long run regardless of the outcome of COVID-19 will be beneficial IMO, I suspect FDA approvals for Leronlimab for HIV and all the other indications will be much easier now that they have seen our drug in action with COVID-19.
I did notice in the PR these changes, or at least I think the numbers changed regarding # of patients, 342 to 390 ?
"The Phase 2b/3 trial for severe and critically ill COVID-19 patients is for 390 patients, double blinded with 2:1 ratio (active drug to placebo ratio). Patients enrolled in this trial are expected to be administered leronlimab for two weeks with the primary endpoint being the mortality rate at 28 days and a secondary endpoint of mortality rate at 14 days. The Company will perform an interim analysis on the data from 50 patients.
I did notice in the PR these changes, or at least I think the numbers changed regarding # of patients, 342 to 390 ?
"The Phase 2b/3 trial for severe and critically ill COVID-19 patients is for 390 patients, double blinded with 2:1 ratio (active drug to placebo ratio). Patients enrolled in this trial are expected to be administered leronlimab for two weeks with the primary endpoint being the mortality rate at 28 days and a secondary endpoint of mortality rate at 14 days. The Company will perform an interim analysis on the data from 50 patients.
(0)
(0)